CR Group L.P. 4
4 · T2 Biosystems, Inc. · Filed May 7, 2024
Insider Transaction Report
Form 4
Capital Royalty L.P.
10% Owner
Transactions
- Award
Common Stock
2024-05-03+2,001,514→ 2,879,929 total(indirect: By CRG Partners III - Parallel Fund B (Cayman) L.P.) - Award
Common Stock
2024-05-03+403,608→ 828,324 total(indirect: By CRG Partners III - Parallel Fund (A) L.P.) - Award
Common Stock
2024-05-03+1,565,445→ 3,548,707 total(indirect: By CRG Partners III (Cayman) Lev AIV I L.P.) - Award
Common Stock
2024-05-03+648,139→ 1,330,175 total(indirect: By CRG Partners III L.P.) - Award
Common Stock
2024-05-03+129,629→ 266,038 total(indirect: By CRG Partners III (Cayman) Unlev AIV I L.P.)
Footnotes (2)
- [F1]Pursuant to that certain Securities Purchase Agreement, dated May 3, 2024, by and among the Company, CRG Partners III L.P., CRG Partners III - Parallel Fund (A) L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III - Parallel Fund B (Cayman) L.P. (collectively, the "CRG Entities"), the CRG Entities received these shares of common stock in exchange for the CRG Entities surrendering for cancellation of certain outstanding debt.
- [F2]CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities.